NLS Pharma Announces New Information In Support Of The Mechanism Of Action Of Its Lead Compound NLS-1 mazindol CR

STANS, Switzerland, May 26, 2017 /PRNewswire/ — NLS Pharma Group (NLS Pharma), a Swiss biotech group focusing on the development of novel treatments for attention deficit hyperactivity disorder (ADHD), sleep disorders, and cognitive impairments, announced today that studies investigating the mechanism of action of mazindol—a dual pan-monoamine reuptake inhibitor/orexin-2 receptor agonist (dual pMRI/OX 2R agonist)—may indicate…